Literature DB >> 2784859

Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome.

C S Shelley1, E Remold-O'Donnell, A E Davis, G A Bruns, F S Rosen, M C Carroll, A S Whitehead.   

Abstract

Sialophorin (CD43) of leukocytes and platelets is a surface sialoglycoprotein that is phenotypically defective on lymphocytes of patients with the X chromosome-linked immunodeficiency Wiskott-Aldrich syndrome. Previous studies with monoclonal antibodies indicate that sialophorin is a component of a T-lymphocyte activation pathway. Here we describe the cDNA cloning and derived amino acid sequence of human sialophorin. The sequence predicts an integral membrane polypeptide with an N-terminal hydrophobic signal region followed by a mucin-like 235-residue extracellular region with a uniform distribution of 46 serine, 47 threonine, and 24 proline residues. This is followed by a 23-residue transmembrane region and a 123-residue C-terminal intracellular region. These latter regions have been highly conserved during evolution; the intracellular region contains a number of potential phosphorylation sites that might mediate transduction of activation signals. The chromosomal location of the sialophorin gene was determined and the implications of this assignment for the pathogenesis of the Wiskott-Aldrich syndrome are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784859      PMCID: PMC287010          DOI: 10.1073/pnas.86.8.2819

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase.

Authors:  F Sanger; A R Coulson
Journal:  J Mol Biol       Date:  1975-05-25       Impact factor: 5.469

2.  The application of 0.1 M quadrol to the microsequence of proteins and the sequence of tryptic peptides.

Authors:  A W Brauer; M N Margolies; E Haber
Journal:  Biochemistry       Date:  1975-07       Impact factor: 3.162

3.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

4.  BrdU-33258 Hoechst analysis of DNA replication in human lymphocytes with supernumerary or structurally abnormal X chromosomes.

Authors:  S A Latt; H F Willard; P S Gerald
Journal:  Chromosoma       Date:  1976-08-17       Impact factor: 4.316

5.  RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination.

Authors:  H Lehrach; D Diamond; J M Wozney; H Boedtker
Journal:  Biochemistry       Date:  1977-10-18       Impact factor: 3.162

6.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

7.  Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity.

Authors:  M D Cooper; H P Chae; J T Lowman; W Krivit; R A Good
Journal:  Am J Med       Date:  1968-04       Impact factor: 4.965

8.  Identification of a glycophorin-like molecule at the cell surface of rat thymocytes.

Authors:  W R Brown; A N Barclay; C A Sunderland; A F Williams
Journal:  Nature       Date:  1981-02-05       Impact factor: 49.962

9.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

10.  Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation.

Authors:  R Parkman; J Rappeport; R Geha; J Belli; R Cassady; R Levey; D G Nathan; F S Rosen
Journal:  N Engl J Med       Date:  1978-04-27       Impact factor: 91.245

View more
  34 in total

Review 1.  CD43, a molecule with multiple functions.

Authors:  Y Rosenstein; A Santana; G Pedraza-Alva
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA.

Authors:  O C Farokhzad; J M Teodoridis; H Park; M A Arnaout; C S Shelley
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

3.  Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures.

Authors:  Maxim A Vodyanik; James A Thomson; Igor I Slukvin
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

Review 4.  Flow cytometric immunophenotyping: principles and pitfalls.

Authors:  M Othmer; F Zepp
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

5.  CD43 interferes with T-lymphocyte adhesion.

Authors:  B Ardman; M A Sikorski; D E Staunton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

6.  Signaling through CD43 regulates CD4 T-cell trafficking.

Authors:  Purvi D Mody; Judy L Cannon; Hozefa S Bandukwala; Kelly M Blaine; Alexander B Schilling; Kevin Swier; Anne I Sperling
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

Review 7.  Wiskott-Aldrich syndrome: a multidisciplinary disease.

Authors:  G R Standen
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

8.  The cleavage of neutrophil leukosialin (CD43) by cathepsin G releases its extracellular domain and triggers its intramembrane proteolysis by presenilin/gamma-secretase.

Authors:  Agnès Mambole; Dominique Baruch; Patrick Nusbaum; Sylvain Bigot; Misa Suzuki; Philippe Lesavre; Minoru Fukuda; Lise Halbwachs-Mecarelli
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

9.  Germ-line mosaicism simulates genetic heterogeneity in Wiskott-Aldrich syndrome.

Authors:  B Arveiler; G de Saint-Basile; A Fischer; C Griscelli; J L Mandel
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

Review 10.  The molecular basis of X-linked immunodeficiency disease.

Authors:  C Kinnon; R Levinsky
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.